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Abstract
Background: In viral disease, infection is controlled at the cellular level by type I interferon (IFN-I), but dengue virus
(DENV) has the ability to inhibit this response. Type III interferon, also known as lambda IFN (IFN-III or IFN-λ), is a
complementary pathway to the antiviral response by IFN-I. This work analyzed the IFN-λ (IFN-III) mediated antiviral
response against DENV serotype 2 (DENV-2) infection.
Methods: Dengue fever patients were sampled to determine their IFN-λ levels by ELISA. To study the IFN-λ
response during DENV infection we selected the epithelial cell line C33-A, and we demonstrated that it is permissive to
DENV-2 infection. The effect of IFN-λ on virus replication was determined in these cells, in parallel to the expression of
IFN-stimulated genes (ISGs), and Suppressor of Cytokine Signaling (SOCS), genes measured by RT-qPCR.
Results: We found increased (~1.8 times) serological IFN-λ in dengue fever patients compared to healthy blood
donors. IFN-λ inhibited DENV-2 replication in a dose-dependent manner in vitro. The reduction of viral titer
corresponded with increased ISG mRNA levels (MX1 and OAS1), with the highest inhibition occurring at ISG’s peak
expression. Presence of IFN-negative regulators, SOCS1 and SOCS3, during DENV-2 infection was associated with
reduced IFN-λ1 expression.
Conclusions: Evidence described here suggests that IFN-λ is a good candidate inhibitor of viral replication in dengue
infection. Mechanisms for the cellular and organismal interplay between DENV and IFN- λ need to be further studied as
they could provide insights into strategies to treat this disease. Furthermore, we report a novel epithelial model to
study dengue infection in vitro.
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Background
Dengue is an important public health problem: Using
updated mapping approaches, there are 390 million esti-
mated dengue infections per year worldwide, of which 96
million manifest clinically at some level of severity [1].
This leads to half a million hospitalizations and 25,000
deaths, mainly in children [2]. The etiological agent of
dengue disease is the dengue virus (DENV), which is re-
sponsible for dengue fever (DF), dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS).
Dengue virus, a member of the Flaviviridae family, is
an enveloped virus containing a ~11 kb genome of
positive single-stranded RNA which encodes three struc-
tural proteins (C, pr-M, E) and seven nonstructural pro-
teins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, NS5) [3].
Four serotypes of dengue virus (DENV-1, DENV-2,
DENV-3, and DENV-4) cause DF and more severe mani-
festations like DHF and DSS [4].
Dengue virus is transmitted by female mosquitoes
mainly of the species Aedes aegypti and A. albopictus.
The disease is widespread throughout the tropics, with
local spatial risk variations influenced strongly by rain-
fall, temperature and unplanned rapid urbanization [5].
In many viral diseases, infection is controlled at the
cellular level by type I interferon (IFN-α/β) produced in
response of viral RNA. Recognition of IFN-I by its spe-
cific cell receptors activates the JAK-STAT signaling
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pathway, which leads to the establishment of an anti-
viral state in the cell. However, viruses possess diverse
strategies to circumvent IFN effects [6].
DENV, like other viruses, has the ability to inhibit this
innate response, which may contribute to its pathogen-
esis. DENV virus induces the activation and release of
high levels of chemokines and pro-inflammatory cyto-
kines in human dendritic cells, although it is a weak
inducer of IFN-I, as it blocks IRF-3 phosphorylation,
impairing subsequent IFN-α/β production [7].
There are three types of IFN. Type I comprises several
subtypes of IFN-α and several other isoforms such as
IFN-β,-ε,-κ,-δ,-ω,-τ and -ζ [8, 9]. Type II contains only
one member, IFN-γ. The latest identified group, type III,
comprises IFN-λ1, IFN-λ2, IFN-λ3 (also named interleu-
kin [IL]-29, IL-28A and IL-28B, respectively) and IFN-λ4
[10–12], but there is limited information about their ex-
pression and biological functions. Furthermore, the role
of IFN-III during DENV infection is unexplored.
IFN-λ specific signaling occurs through its receptor
on the cell membrane, which consists of two subunits:
IL28R1 (also named IFN-λR1, IL28Rα) and IL-10 recep-
tor 2 (IL-10R2) [8, 10, 11]. Most cells express the IL-
10R2 subunit, but IL28R1 distribution appears to be
much more restricted. The receptor for IFN-λ is expressed
preferentially in cells of epithelial origin and in some cells
of the immune system [8, 10, 13].
Binding of IFN-λ to its receptor leads to the activation
of JAK1 and Tyk2, which mediate the phosphorylation of
STAT1 and STAT2 proteins. STAT phosphorylation leads
to their dimerization, binding to IRF9 and translocation
into the nucleus where they regulate the expression of
specific genes. IFN-III has similar functions to IFN-I, in-
ducing an antiviral state in cells [8, 10, 13] and mediates
the antiviral response against several human pathogens
including hepatitis B virus, hepatitis C virus and human
immunodeficiency virus [13–15]. The restricted expres-
sion of its receptor suggests that the IFN-λ could exert an
antiviral role on certain cell types [16, 17].
There is no commercial vaccine or specific antiviral
treatment for dengue; thus, the development of efficient
therapeutic strategies against this common and some-
times severe infection is urgent. The antiviral activity of
interferons has been observed in diverse clinical studies
showing a relative efficiency against different viral infec-
tions. In 1984, Limonta Vidal et al. [18] introduced the
use of leukocyte interferon to treat children with dengue,
showing a significant decrease in the number of compli-
cations and deaths when interferon was applied. How-
ever, the clinical use of interferon to treat dengue is not
common, possibly due to IFN-α side effects associated
with its systemic activity. IFN- λ is an attractive treat-
ment alternative because it elicits a satisfactory antiviral
activity with only a minor secondary response [19, 20].
Nevertheless, DENV has developed mechanisms to evade
the immune response. Therefore, the precise analysis of
IFN- λ response during dengue infection is crucial to
evaluate/predict its potential clinical uses in this disease.
The present work focuses on the effect in epithelial
cells of IFN-λ (IFN-III) on the DENV-2 infection. We
found higher levels of IFN-λ in dengue fever patients
compared with healthy blood donors and we provide
evidence that endogenous and exogenous IFN-λ inhibit
DENV-2 replication in the C33-A cell line.
Results
IFN-λ levels in patients with dengue fever
To detect the presence of IFN-λ during DENV infection,
serum samples from patients with dengue fever were ana-
lyzed by ELISA. Levels of IFN-λ (λ1/λ3) were determined
in serum samples from 10 patients with dengue fever and
10 healthy blood donors. Figure 1 shows the value distri-
bution for each group; the mean was 106.9 ± 9.05 pg/ml
for DF patients and 58.71 ± 6.86 pg/ml (p < 0.001) for
healthy donors.
C33-A cells are permissive to DENV-2 infection
To study the response of IFN-λ during DENV-2 infec-
tion, we selected the epithelial cell line C33-A. Because
DENV infection has not been reported infecting C33-A
cells, we performed initial assays and analyzed whether
these cells are permissive to infection. After DENV-2
replication in C33-A cells, viral titers in the superna-
tants at 48 h post-infection were quantified by lytic
plaque assays in BHK-21 cells, meaning that infectious
viral progeny was released from C33-A cells. Immuno-
fluorescence analysis using a specific antibody against
DENV pr-M protein (Fig. 2) confirmed that C33-A cells
Fig. 1 Dengue fever patients enhance their IFN-λ1 levels in blood.
IFN-λ1/λ3 levels (pg/ml) in serums from clinical dengue patients and
healthy donors were measured by ELISA. The experiment was done
by triplicate and reproduced once. Error bars represent standard
deviations, *** means p < 0.001
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are permissive to DENV-2 infection. Specific fluores-
cence was found in the cytoplasm of infected cells.
With these data we propose the C33-A cell line as a
novel epithelial model to analyze the relationship be-
tween DENV-2 infection and IFN-λ.
DENV-2 infection and IFN-λ1 increase the expression of
IL28R1 in C33-A cells
To analyze the effect of DENV-2 infection on signal
transduction initiated by IFN-III, the tissue-specific
IL28R1 subunit of type-III interferon receptor was quan-
tified on C33-A cells, by immunofluorescence. Figure 3b
shows the presence of IL28R1 at significant levels on the
cell membrane of non-infected cells (red signal). Expres-
sion of this subunit increased 76 % in the presence of
IFN-λ1 (Fig. 3f ) and 61 % during DENV-2 infection
(Fig. 3d) with respect to untreated cells (quantification
shown in Fig. 3g). Thus, DENV-2 and IFN-λ1 upregulate
to a similar extent the expression of the IL28R1 subunit
of the IFN-III receptor, suggesting that differential ef-
fects between these two stimuli may lie at other points
in the IFN-λ signal transduction pathway.
DENV-2 replication induces the expression of IFN-λ genes
To determine whether DENV-2 induces the expression
of all subtypes of IFN-λs, four treatments were com-
pared: Mock infection, IFN-λ1 treatment only (35 ng/
ml), DENV-infection only (MOI = 0.1), and IFN-λ1 treat-
ment followed by DENV infection. Mock-infected cells
had no RT-PCR product for any of the IFN-λ isoforms
(Fig. 4a). In contrast, IFN-λ1, IFN-λ2 and IFN-λ3 tran-
scripts were demonstrated by end-point RT-PCR under
the other three conditions studied (Fig. 4a).
To corroborate this result, total protein extracts from
each condition were used for Western blot with specific
antibodies against two subtypes of IFN-III (λ1 and λ2).
Figure 4b shows that IFN-λ1 and IFN-λ2 are strongly
induced by DENV-2 infection.
IFN-λ1 and IFN-λ2 inhibit DENV-2 replication in a
dose-dependent manner
To explore the effect of IFN-λ1 and IFN-λ2 on the
DENV-2 infection, a replication inhibition curve was
determined. C33-A cells were pretreated with increas-
ing concentrations of IFN-λ1, IFN-λ2 (0, 10, 20, 30 and
Fig. 2 Permissivity of C33-A cells to DENV-2 infection. Cells were infected with dengue virus (MOI = 0.1) for 2 h, maintained for 24 h, washed, and
fixed with methanol-acetone. The virus was detected using antibodies against the viral pr-M protein and a Texas Red secondary antibody and
observed with fluorescence microscopy. a–c DENV-2-infected cells. d–f Mock-infected cells. a, d White light. b, e Fluorescence, (c, f) Merged
images. Bars = 30 μm
Palma-Ocampo et al. Virology Journal  (2015) 12:150 Page 3 of 14
40 ng/ml) or IFN-α (0, 100, 200, 300 and 400 IU/ml)
prior to infection with DENV-2 (MOI = 0.1). Forty-
eight hours after infection, the supernatants from each
condition were quantified by lytic plaque-forming as-
says (Fig. 5).
Figure 5 shows that IFN-λ1 and IFN-λ2 inhibited
DENV-2 replication in a dose-dependent manner, with
relatively high inhibitory effect: IC50 = 8.705 ng/ml,
IC90 = 17.78 ng/ml for IFN-λ1 (Fig. 5b) and IC50 =
8.24 ng/ml, IC90 = 16.2 ng/ml) for IFN-λ2 (Fig. 5c);
whereas the IC50 for IFN-α was 122–138 IU/ml and
IC90 = 380-398 IU/ml (Fig. 5a). These experiments
showed that exogenous administration of IFN-λ prior
to infection reduces the viral titer of DENV-2.
Subsequently, viral replication in the C33-A cells was
determined on lytic plaque-forming assays at different
time post-infection (0, 6, 12, 18, 24 and 48 h). Two in-
fectious doses (MOI = 0.1 and 1.0) were assayed. Cells
pretreated with 10 ng/ml of IFN-λ1 (Fig. 6a) or IFN-λ2
(Fig. 6b) for 6 h prior to infection were compared to
cells that were infected but not treated with IFN. The
plots show an equivalent effect of IFN-λ1 and IFN-λ2
pre-treatment on viral titers, which were reduced by
1.5–2 logs with respect to mock-treated cells.
IFN-λ1 inhibits DENV-2 replication in cells lacking
type I IFN
To determine whether IFN-λ1 is enough to inhibit rep-
lication of DENV-2, we tested its ability to inhibit viral
replication in the absence of INF-α. Inhibition experi-
ments were similar to those described in Fig. 5, but
they were performed on Vero cells that do not produce
IFN-α, yet respond to it if supplied externally [21]. Vero
cells were pre-incubated for 6 h with increasing con-
centrations of IFN-α, IFN-λ1 or IFN-λ1 plus IFN-α and
then infected with DENV-2. By itself, IFN-λ1 treatment
decreased the viral progeny 50 % at 37.15 ng/ml (IC50)
(Fig. 7b). Treatment with IFN-λ1 plus IFN-α had a lower
IC50 of 14.12 ng/ml calculated for IFN-λ1 (Fig. 7c); while
for IFN-α treatment alone, IC50 couldn’t be calculated
Fig. 3 Membrane receptor expression IL28R in C33-A cells. The presence of IL28R1 was determined in C33-A cells: (a, b) Mock-infected.
(c, d) DENV-2 infected (MOI = 0.1). e, f Treated with IFN-λ1 (35 ng/ml). Immunofluorescence was detected with anti-IL28R1 and CFL647-conjugated
secondary antibody and observed by fluorescent microscopy (40X magnification). g Fluorescence intensities were determined by analysis of three
different fields by randomly counting 50 cells using the image analysis software EZ-C1 v.2.3. *p < 0.05, ***p < 0.001. Nuclei were stained with the green
fluorescent dye Sybr-14. Bars = 30 μm
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because the 50 % inhibition was not reached under the ex-
perimental conditions (Fig. 7a). This experiment suggests
that IFN-λ1 is able to inhibit DENV-2 infection, but an ef-
fective response likely involves both types of interferons
and a possible synergism between them.
Pre-treatment with IFN-λ1 induces expression of ISGs that
prevents viral replication
Expression kinetics of IFN-stimulated genes (ISGs) was
analyzed in C33-A cells by quantitative real-time PCR
(RT-qPCR) for the same experimental groups described
in Fig. 4 (Mock infection, IFN-λ1 treatment, DENV-
infection and IFN-λ1 followed by DENV infection). For
this analysis, we selected the OAS1 and MX1 genes as
indicative of interferon pathway functionality for the
antiviral response, the IFN-λ1 and IFN-β genes, and two
negative regulatory genes, SOCS1 and SOCS3.
Figure 8a shows that stimulation of C33-A cells with
IFN-λ1 slightly increases the transcription of OAS1 to
similar levels between 6 and 48 h post-treatment (pt).
DENV-2 infection significantly increases OAS1 mRNA
but at earlier times, peaking at 6 h post-infection. How-
ever, the most striking effect was present with IFN-λ1
pre-treatment followed by DENV-2 infection, that
showed a pronounced increase in OAS1 expression
from 6 to 18 h post-infection, at which time it peaked
and then underwent a slow steady decrease, remaining
Fig. 5 IFN-λ inhibits DENV-2 replication in a dose-dependent
manner. C33-A cells were treated with increasing concentrations
of IFN-α (a), IFN-λ1 (b) or IFN-λ2 (c) and then infected by DENV-2
(MOI = 0.1). Forty-eight hours post-infection, the viral titer was
obtained by plaque assay. The doses used were 10–40 ng/mL for
IFNλ1 or IFN-λ2 and 100–400 UI/ml for IFN-α. Plots show the
percentage inhibition of the viral titer in each group compared
to untreated cells. Dotted lines represent the IC50 values corresponding
to IFN-λ1 = 8.705 ng/ml, IFN-λ2 = 8.24 ng/ml, IFN-α= 122–138 IU/ml. The
points are representative of two independent experiments performed
in triplicate. Experiments were fit to the Hill equation, using nonlinear
regression to estimate the IC50 of IFN-λ1, IFN-λ2 or IFN-α (concentration
of IFN that inhibited DENV-PFU production by 50 %, compared with
parallel IFN free infected cultures). These IC50 values were considered for
subsequent experimental procedures
Fig. 4 DENV-2 induces the expression of IFN-III in C33-A cells.
C33-A cells were treated with IFN-λ1 (35 ng/ml) infected with
DENV-2 (MOI = 0.1) or pre-treated with IFN-λ1 and subsequently
infected with DENV-2. Forty-eight h post-infection, total cellular
RNA was isolated and used in end-point RT-PCR for qualitative
determination of the IFN-λ1, IFN-λ2, IFN-λ3 genes, using HPRT as
an endogenous control gene. a Results of RT-PCR amplification of
mock-infected and the three experimental conditions are shown.
b Extracts of total protein from each condition were used for
Western blotting to determine the presence of IFN-λ1 and IFN-λ2
proteins. Actin was the loading control. A semi quantitative
analysis of detected bands normalized to actin was performed
using ImageJ software (http://rsb.info.nih.gov/ij/)
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high at 24 and 48 h. This result suggests that IFN-λ1
decreases DENV-2 replication in part by viral mRNA
degradation via RNase L. Moreover, stimulation of cells
with IFN-λ1 dramatically increases MX1 gene transcrip-
tion, suggesting that the efficient activation of IFN-III
signal transduction is useful in controlling DENV-2 infec-
tion. IFN-λ1 treatment induced a bimodal MX1 in-
crease with a first peak at 6 h post-infection and a
second peak nearly 100-fold higher than basal at 24 h
(Fig. 8b). Bimodality probably is due as a result of a first
wave of activation by IFN-β and IFN-λ1 and subse-
quently, the increase at 24 h could be by IFN-λ2, which
has demonstrated late induction, as well as by the late
wave of endogenous interferons [22]. MX1 mRNA was
detected at similar levels in infected and non-infected
cells at all the studied times, suggesting that DENV
induces an impairment in IFN signal transduction;
however, this experiment cannot discriminate between
IFN-I or IFN-III specific pathways. In cells pre-treated
with IFN-λ1 and then infected, MX1 mRNA increased
between 18 and 48 h post-infection, although not as
much as OAS1.
To determine if DENV-2 has differential effects on the
activation of IFN-I and IFN-III, mRNA levels of IFN-β
(IFN-I) and IFN-λ1 (IFN-III) were quantified. Figure 8c
shows that IFN-β mRNA is not increased at all in cells
infected with DENV-2 at any of the studied times. IFN-
λ1 stimulation increased IFN-β mRNA ~20–30 times
between 6 and 24 h post-treatment. In contrast, IFN-λ1
pre-treatment followed by DENV-2 infection showed a
<10-fold increase in IFN-β mRNA, remaining much
lower than with IFN-λ1 stimulation alone. Therefore, it
is believe that DENV-2 could affect the transcription of
the IFN-β gene, probably by affecting IRFs.
In contrast, the three experimental conditions induced
intense, bimodal stimulation of IFN-λ1 expression, with
peaks at 6 and 48 h post treatment (Fig. 8d). IFN-λ1 treat-
ment alone, increased IFN-λ1 mRNA 70-fold at 6 h and
170-fold at 48 h post-treatment; while DENV-2 and
IFN-λ1 treatment followed by infection increased IFN-
λ1 levels somewhat less (65-fold and 55-fold for
DENV-2 and 40-fold and 120-fold for IFN-λ1/DENV-2,
at 6 h and 48 h post-infection, respectively). The similar
expression kinetics in Fig. 8b and c, in contrast to
Fig. 8d, suggests that the inhibition of MX1 transcrip-
tion in DENV-2 infection could be due primarily to
lack of IFN-I.
Other important factors in the IFN pathway are the
negative regulators SOCS1 and SOCS3, which increased
from 12 h post infection (Fig. 8e and f). It is noteworthy
that DENV-2 infection induces a significant SOCS1 in-
crease that peaks at 24 h (40-fold), whereas in IFN-λ1
stimulation and subsequent infection this increase was
impaired and reached only 20-fold at 24 h.
Increase in SOCS1 mRNA coincides with a decrease in
IFN-λ1 transcription
In order to analyze other aspects of expression kinetics,
the same data from Fig. 8 were re-plotted in Fig. 9 but
grouped by experimental condition. Control cells (mock-
infected) did not show significant activation of any gene
tested, indicating that an external stimulus is required to
activate their transcription in the evaluated conditions
(Fig. 9a).
IFN-λ1 mRNA peaked at 6–12 h and 48 h post-
treatment (Fig. 9b). DENV-2 infection stimulated the
transcription of IFN-λ1, but the maximum value at 48 h
post-treatment and was 65 % lower than in IFN-λ1
treated cells (open circles in Fig. 9b vs c).
For OAS1, the highest mRNA level was observed in
cells treated with IFN-λ1/DENV-2 at 18 h post-infection
(Fig. 9d). DENV-2 infection increased the IFN-λ1 tran-
scription compared to non-infected cells treated with
Fig. 6 Kinetics of DENV-2 infection inhibition by IFN-λ. C33-A cells were
untreated or treated with 10 ng/ml of (a) IFN-λ1 or (b) IFN-λ2 for 6 h
prior to infection with DENV-2, which was performed at two different
infectious doses (MOI = 0.1 and 1.0). The viral supernatant was titrated
by plaque assays at 0, 6, 12, 18, 24 and 48 h post-infection. The points
are representative of two independent experiments performed
in triplicate
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Fig. 7 (See legend on next page.)
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IFN-λ1. Conversely, the highest level of MX1 transcript
was observed in the IFN-λ1-treated group at 6 h (40-fold)
and 24 h (90-fold) (Fig. 9c). In addition, a steady increase
in MX1 starting at 12 h post-infection and reaching
25-fold, was observed in the IFN-λ1/DENV-2 group
(Fig. 9d). This increase was smaller than in cells stimu-
lated only by IFN-λ1 (Fig. 9c) and it is of particular
interest because the DENV-2-infected group did not
show a significant increase in MX1 expression at any
of the evaluated times.
The IFN negative regulators SOCS1 and SOCS3 showed
maximum amounts at 6–12 h and 24 h post-stimulation
with IFN-λ1. DENV2 infection also elicited an increment
in their expression which was much stronger for SOCS1.
Their activation coincided with that observed after
DENV-2 infection but was even stronger. The IFN-λ1/
DENV-2 experimental condition showed the highest
expression of both genes at 12 h post-infection but it
dropped to 40 % of the DENV-2-only expression level
by 48 h post-infection. It was also evident that the peak
(See figure on previous page.)
Fig. 7 IFN-λ1 inhibits DENV-2 replication in cells lacking type I IFN. Vero cells were treated with increasing concentrations of IFN-α (a) or IFN-λ1
(b) or IFN-λ1 plus IFN-α (c), and then infected by DENV-2 (MOI = 0.1). The doses used were 10–40 ng/ml of IFN-λ1 or 100–400 UI/ml of IFN-α.
Forty-eight hours post-infection, the viral titer was obtained by plaque assay. Plots show the percentage inhibition of the viral titer in each group compared
to untreated cells. Dotted lines represent the IC50 values corresponding to IFN-λ1 = 37.15 ng/ml, IFN-λ1 in presence of IFN-α= 14.12 ng/ml, the value of
IC50 for IFN-α was not calculated because 50 % inhibition was not reached under the conditions of experiment. Error bars represent standard deviations of
means from two independent experiment *p< 0.01, **p< 0.001
Fig. 8 Transcription levels of IFN-stimulated genes during DENV-2 infection. Expression of OAS1 (a), MX1 (b), IFN-β (c), IFN-λ1 (d), SOCS1 (e), and
SOCS3 genes (f) in cells infected with DENV-2 (MOI = 0.1) or treated with 10 ng/ml of IFN-λ1 or treated with IFN-λ1 before DENV-2 infection, were
determined by RT-qPCR at 0, 6, 12, 18, 24, and 48 h post-infection or post-treatment. Results are presented as expression relative to untreated
cells, which have a value of 1. mRNA levels were normalized to the HPRT gene. Data points represent the mean of three replicates and error bars
indicate standard deviation
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of SOCS1 expression during DENV-2 infection, coin-
cided with a drop in IFN-λ1 expression (Fig. 9b).
Discussion
IFN-III is the most recently identified interferon group
[10–12], and there is limited information about its ex-
pression and biological functions. The particular role of
IFN-III during DENV infection is unexplored. Although
most cells respond to IFN-I, certain cell types, especially
epithelial cells, can respond to IFN-III due to the restric-
tion in receptor IL28R1 expression [23, 24].
In the present work we demonstrated that dengue
fever patients had ~1.8 times higher IFN-λ levels com-
pared to healthy blood donors (p < 0.001). We are con-
ducting further studies to answer whether IFN-λ plays
a role in viral clearance or in the generation of specific
clinical outcomes. For IFN-α, for instance, a recent
study found higher levels in DF than DHF patients in-
fected by DENV-1 or 2, that declined rapidly at day 3
after fever onset [25]. Such studies require the analysis
of many patients, the determination of disease severity
and the inclusion of patients infected with different
DENV serotypes, among other variables.
Epithelial cells are IFN-III’s main target. An analysis of
IL28R1 receptor expression in mouse cells showed that
vaginal epithelium and keratinocytes but not fibroblasts
respond to IFN-λ [23]. Several studies have been con-
ducted in cell lines and primary cell cultures to study
IFN-λ response [26]. In the present study we found that
the C33-A cervical, epithelial cell line is permissive to
DENV-2 infection and that this cell line both produces
and responds to IFN-λ. IL28R1, which is essential to
support the antiviral action of IFN-λ, is expressed in
C33-A cells. IL28R1 expression is inducible under viral
infections, concurrent with the expression of IFN-λ [16].
Accordingly, IL28R1 expression increased during DENV-2
infection in C33-A cells, which could potentiate the effect
of IFN-λ signalling, leading to stimulation of gene tran-
scription for the antiviral response and to inhibition of
DENV-2 replication; as has been demonstrated for HCV,
HIV and HBV infections [15, 27].
The present study demonstrated the ability of IFN-λ
in the inhibition of DENV-2 replication. IFN-λ reduced
the amount of infectious particles secreted into the
supernatant of C33-A cultures, quantified by plaque as-
says. Treatment with IFN-λ or IFN-α decreased the
viral titer. Dose-response experiments showed that the
IC50 values for IFN-λ1 and IFN-λ2 were 8.24 ng/ml
and 8.705 ng/ml, respectively (Fig. 5). In view of these
IC50 values, we tested whether an IFN- λ concentration
of 10 ng/ml, which produces optimal gene induction in
other viral infections [28, 29], could induce the expression
Fig. 9 Increase in SOCS1 coincides with a fall in IFN-λ1 transcription. The same values used in the graphs of Fig. 8 were re-plotted and sorted
according to experimental condition: (a) mock-infected cells, (b) infected with DENV-2 (MOI = 0.1), (c) treated with 10 ng/ml of IFN-λ1 or
(d) treated with IFN-λ1 prior DENV-2 infection. Data points represent the mean of three replicates and error bars indicate standard deviation
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of antiviral response genes during dengue infection. In a
study involving West Nile virus (WNV), another mem-
ber of the Flaviviridae family, induction of IFN-λ and
JAK/STAT pathway activation was demonstrated in in-
fected cells. IFN-λ was able to prevent WNV infection
of naïve cells, but failed to inhibit viral replication in
cells once infection had been established, likely due to
IFN-λ inhibition [30].
Furthermore, we report the IFN-λ1-mediated inhib-
ition of DENV-2 replication in Vero cells, which are de-
void of IFN-I, but have functional IFN-III responses.
These data suggest that dengue virus and the IFN-λ
treatment can active ISGs without type I IFNs. However,
pre-treatment with IFN-λ1 before dengue infection was
not able to inhibit viral replication to the same degree in
Vero as in C33-A cells, which shows that dengue virus
can block activated signalling pathways that induce both
type I and III interferons. Since viral titers did not de-
crease markedly with the highest IFN-λ1 doses used, the
data suggest that viral replication can be inhibited, albeit
weakly, by endogenous and exogenous IFN-λ1 in com-
plete absence of IFN-I. Furthermore, the reduction in viral
progeny observed with IFN-λ1+ IFN-α, suggests that
both interferons work synergistically. Importantly, the
MX1 gene can be induced in Vero cells stimulated
with recombinant type I interferon, thus demonstrat-
ing that although these cells don’t produce IFN-I they
respond to it [21, 31, 32].
The antiviral effect shown by IFN-III could occur
through the stimulation of antiviral genes as cells were
first treated with IFN-λ1 and then infected. It is note-
worthy that DENV-2 infection induced ISG transcripts
but that these did not reach the levels observed when
cells were stimulated with IFN-λ1. However, when cells
were pre-treated with IFN-λ1 and then infected, ISG
transcript levels were significantly higher and were
maintained longer than in the DENV-2-infected group.
SOCS1 and SOCS3 were induced after ISGs reached
their highest peaks, which may denote the negative ac-
tion exerted on the IFN-activated JAK/STAT pathway.
However, the analyzed ISGs in the presence of IFN-λ1
stimulation remained at low levels but were sufficient
to reach a second expression peak capable of inhibiting
viral replication at late stages, which explains the de-
crease in viral titers observed between 18 and 48 h
(Fig. 6).
The antiviral genes MX1 and OAS1 showed an early
activation at 6 h and peaked at 18 and 48 h, respect-
ively, in the IFN-λ1/DENV-2 group. OAS1 mRNA was
higher when cells were pre-treated with IFN-λ1 and
subsequently infected compared to cells that were stim-
ulated only with IFN-λ1. This outcome was likely due
to increased activation of the gene in the presence of
infection plus gene activation mediated by interferon.
OAS1 has antiviral activity against DENV-2 infection
[33]. The OAS/RNase L antiviral system is induced via
IFN and plays a critical role in innate immunity, control-
ling the production of viral particles. RNase L possesses
antiviral action, cleaving the viral RNA, inducing apop-
tosis in infected cells, and increasing the production of
IFN-β through MDA5/RIG-I/IPS-I [34].
Higher activation of the MX1 gene occurs through
stimulation of IFN-λ1 because it is a gene-specific inter-
feron response, which indicates the proper functioning
of the pathway in the cell line. In the case of the IFN-
λ1/DENV-2 experiments, increased expression was most
likely caused by pre-treatment with IFN-λ1 because the
DENV-2-infected group showed no transcript increase
for this gene. It is significant that although the transcript
levels were as high as when cells were stimulated only
with IFN-λ1, the observed levels may be sufficient to in-
hibit viral replication even with the activation of the
SOCS genes, whose levels appear not be sufficient to
completely inhibit the transcription of MX1 at later
times.
Transcription levels of ISGs in different groups showed
a clear relationship between treatment with IFN-λ and its
role in inhibition of DENV-2 replication. It is possible to
observe a process of evasion of the immune response,
most likely mediated by viral infection, showing a decrease
in the transcription of evaluated ISGs in DENV-2 infected
cells compared with cells stimulated with IFN-λ and an
increase in SOCS1 and SOCS3 genes.
However, the IFN-λ1 gene was activated initially and
then in the last times evaluated (6 and 48 h post-
infection), suggesting its escape from the suppressor ac-
tivity of SOCS proteins. When cells were stimulated with
IFN-λ1 and then infected, there was a slight and steady
increase in the evaluated ISGs, which peaked at 12 or 18
and 48 h post-infection, suggesting that activity of the
pathway is only partially affected by viral evasion. These
findings suggest that IFN-I and IFN-III are not always
concomitantly expressed and support the idea that there
are differences in the regulatory mechanisms of their
expression and in the group of genes that can be indi-
vidually or jointly activated [35].
It is noteworthy that the highest peaks of the evalu-
ated ISGs (12 and 18 h) corresponded to the time when
the viral titer was reduced in culture supernatants; thus,
greater inhibition of viral titer was achieved when ISGs
reached their peaks (48 h). These findings suggest that
inhibition of viral titer was caused by IFN-λ treatment
and by the activation of genes in response to interferon,
whose antiviral action in the cells inhibited the replica-
tion of DENV-2.
IFN-λ production increases after treatment with IFN-
α prior to viral infection [36, 37]. Our results suggest
that IFN-III enhances the expression of IFN-I as pre-
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treatment with IFN-λ1 increased IFN-β expression during
infection with dengue virus. This leads us to propose that
the crosstalk between interferon type I and III pathways
may exist in some cells, like mononuclear or plasmacytoid
dendritic cells, to produce and respond to both types of
interferon [38, 39]. However, these are not necessarily re-
dundant systems as shown in our experiments, wherein
the expression of IFN-λ1 exists despite the evasion of the
immune response mounted by DENV-2.
In the absence of antiviral drugs against DENV, this
paper suggests that interferon lambda could be a valu-
able candidate to explore in clinical studies. In addition,
the immunomodulatory properties reported for IFN-λ
[13] can contribute to the regulation of the inflammatory
process characteristic of dengue. Studies with IFN-α in
Japanese encephalitis models have shown decreased in-
flammation [40], but treatment with IFN-α has side
effects associated with the ubiquitous expression of its
receptor [19, 20, 41]. In contrast, the narrow expression
of type III interferon receptor could considerably dimin-
ish side effects of IFN-λ clinical use.
Conclusions
This is the first report of increased levels of IFN-III in
dengue fever patients in vivo and of the antiviral effect
of IFN-III on DENV-2 infection in vitro; however, as-
pects of the activation of this pathway and its crosstalk
with IFN-I remain unanswered.
The epithelial cell line C33-A is a useful model for in
vitro mechanistic studies on DENV replication and its
interaction with the innate response led by IFN-III. In
infection studies, IFN-λ1 and IFN-λ2 inhibited DENV-2
replication in a dose-dependent manner. In Vero cells,
which do not produce IFN-α, viral replication inhibition
by exogenous IFN-λ1 was also observed, although at
higher concentrations, suggesting that IFN-λ1 itself can
inhibit the infection, however the potential to decrease
the viral load increases with the presence of IFN-α.
DENV-2 infection induces IFN-λ1 expression but not of
IFN-β. Exogenous IFN-λ1 induced the transcription of
several ISGs whose expression peaks corresponded to
the time when viral titer was reduced in culture superna-
tants (12, 18, and 48 h post-infection). The present work
opens the possibility for the study of other interactions
and mechanisms of DENV infection with IFN-III in this
cell model and presents an opportunity to consider this
type of IFN as a feasible candidate for the inhibition of
infection in dengue patients.
Methods
Cells
Human cervical carcinoma C33-A (ATCC: CRM-HTB-31),
African green monkey kidney Vero (ATCC: CCL81, kindly
donated by Dr. Judith González, Universidad Autónoma
del Estado de Morelos, Mexico) and baby hamster kidney
BHK-21 (C-13) (ATCC: CCL-10) cell lines were main-
tained in Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10 % fetal calf serum, 100 U/mL peni-
cillin and 100 μg/mL streptomycin at 37 °C with 5 % CO2.
Aedes albopictus C6/36 cells (kindly donated by Dr. Celso
Ramos, Instituto Nacional de Salud Pública, Cuernavaca,
Mexico) were maintained in Minimum Essential Medium
(MEM) supplemented with 10 % fetal calf serum, 100 U/
mL penicillin and 100 μg/mL at 27 °C.
Virus
Dengue virus serotype 2 (Thailand/16681/1984) (DENV-2)
used in this study was kindly provided by Dr. Alvaro
Aguilar-Setien. DENV-2 was replicated in C6/36 cells and
titrated by plaque assay in BHK-21 cells [42].
Clinical samples
Serum samples from dengue patients collected from
June to September 2013, were analyzed to determine the
IFN-λ. All serum samples were maintained at -70 °C,
thawed onto ice and immediately subjected to ELISA.
Patients were recruited in the Regional Hospital at
Mepetec, Puebla, Mexico. All patients had signs of den-
gue fever and DENV infection was confirmed by IgM
antibodies and viral NS1 antigen detection. The samples
from included patients were obtained between days 3
and 5 after fever onset. Sampling and patient informa-
tion management were performed following ethical reg-
ulations approved by Local Research and Health Ethics
Committee #2101 of Mexican Institute for Social Secur-
ity, IMSS (Protocol: R-2011-2103-24) and in accordance
with the Declaration of Helsinki. Written informed con-
sent was obtained from each participant. Controls were
serum samples of healthy blood donors submitted to
conventional studies at the hospital blood bank and were
used to compare IFN-λ levels.
Infection assays
C33-A or Vero cells were seeded onto 12- or 24-well
plates and infected with different virus doses [quanti-
fied by multiplicity of infection (MOI)]. Viral inocula
were incubated for 1 h and then discarded. Cells were
washed twice to eliminate non-adsorbed virus. Fresh
medium (SFB 2.5 %) was added to the cells and then in-
cubated for hours or days depending on the specific
assay.
Cell stimulation
Cells were treated prior to infection for 6 h with 100–500
UI/ml of IFN-α (Probiomed, Mexico city, Mexico.),
10–50 ng/ml of IFN-λ1 (PeproTech, Rocky Hill, NJ,
USA) or 10–50 ng/ml IFN-λ2 (PeproTech). A poly(I:C)
(InvivoGen, San Diego, CA, USA) control treatment
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was performed on cells using DMEM without SFB and
100 μg/ml of poly(I:C).
Western blot
Infected cells or mock-infected cells, previously treated
or mock-treated with IFNs for 6 h, were analyzed in
order to determine the induction of IFN-λ1 and IFN-λ2.
Total extracts of cells were obtained 48 h post-infection
and subjected to SDS-PAGE using a 15 % resolving gel.
Proteins in gel were transferred to PVDF membranes
and detected by anti-IFN-λ1 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA, sc-67642), anti-IFN-λ2 (Abcam,
Cambridge, MA, USA, ab109820) and anti-β-actin spe-
cific antibodies (Abcam, mAbcam8226). Primary anti-
bodies were revealed with a goat anti-rabbit IgG-HRP
(Santa Cruz Biotechnology, sc-2004), rabbit anti-goat
IgG-HRP (Abcam, ab6741) or goat anti-mouse IgG-HRP
(ab97023) and the Immobilon Western chemilumines-
cence system (Millipore-Merck, Darmstadt, Germany).
Fluorescence microscopy
C33-A cells were seeded onto glass chamber slides
(Lab-Tek, Nalgene Nunc, Rochester, NY, USA) and in-
fected as mentioned above. Infected or non-infected
controls were washed with phosphate-buffered saline
(PBS) and fixed in ethanol/acetone 50 % v/v for 10 min
at room temperature. Cells were permeabilized with
0.2 % Triton-X100 for 2 min in order to detect the viral
pr-M protein inside infected cells and incubated in
blocking solution (PBS with 10 % FBS and 0.2 % Tween
20). Cells were labelled with anti-dengue virus pr-M
antibody (Abcam, ab41473) or anti-IL28R (Santa Cruz
Biotechnology, sc-66541), washed and incubated with
rabbit anti-mouse IgG-Texas red (Abcam, ab6726) or
bovine anti-goat IgG-CFL-647 (Santa Cruz Biotechnol-
ogy, sc-362284) for 1 h at room temperature. SYBR-14
dye (Molecular Probes, Eugene, OR, USA) was used to
stain the nuclei. The stained cells were visualized by
laser confocal microscopy system E600-C1 using the
image analysis software EZ-C1 (Nikon).
Real time PCR
Total RNA of DENV-2 infected and/or stimulated cells
was extracted using Trizol (Invitrogen, Carlsbad, CA,
USA) according to the manufacturer’s instructions,
treated with DNase I (Thermo Scientific, Waltham,
MA, USA) and quantified at 260/280 nm. Reverse tran-
scription was performed using RevertAid H Minus Re-
verse Transcriptase kit (Thermo Scientific) and random
hexamers. The reaction program was 25 °C for 10 min,
42 °C for 60 min and 70 °C for 10 min. The obtained
cDNA was used to amplify the IFN-β, OAS1 and MX1
genes using the Taqman Universal PCR Master Mix, no
AmpErase UNG kit (Applied Biosystems, Foster City,
CA, USA). IFN-λ1, SOCS1 and SOCS3 genes were
amplified using Maxima SYBR Green/ROX qPCR Master
Mix (Thermo Scientific). The reaction mixture contained
5 μl 2X Master Mix, 200 nM of each sense and antisense
primer, 200 nM of Taqman probe and 35–50 ng RNA in a
final volume of 10 μl. Forty PCR cycles were performed at
Table 1 Primers used in the present study
Gene name and accession
number in GenBank
Sequence (5′–3′) UPL sequence (UPL#)a Amplicon
bp
Alignmentb
MX1 TCCAGCCACCATTCCAAG TTCTCCTG (2) 60 868–885
NM_001144925.2 CAACAAGTTAAATGGTATCACAGAGC 927–902
OAS1 GGTGGAGTTCGATGTGCTG CCAGGGCA (37) 64 538–556
XM_006719434.1 AGGTTTATAGCCGCCAGTCA 601–582
IFN-β CTTTGCTATTTTCAGACAAGATTCA CTGGCTGG (20) 69 336–360
NM_002176.2 GCCAGGAGGTTCTCAAGAAT 404–389
IFN-λ1 TCCTAGACCAGCCCCTTCA c 73 435–453
NM_172140.1 GTGGGCTGAGGCTGGATA 507–490
IFN-λ2 CCTGGTGGACGTCTTGGA c 84 406–423
NM_172138.1 GTGGGCTGAGGCTGGATA 489–472
IFN-λ3 AGGGCCAAAGATGCCTTAG c 123 167–185
NM_172139.2 CAGCTCAGCCTCCAAAGC 298–281
HPRT1 – – 127 –
NM_000194.2d
aUPL: Universal Probe Library, Roche Life Science. Number of the probe is in parentheses
bPosition of primers in the corresponding gene sequences
cSybrGreen dye was used
dSpecific gene positions and sequences of Applied Biosystems primers and probes are not disclosed
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50 °C for 2 min, 94 °C for 10 min, 95 °C for 15 s, 60 °C for
30 s and 72 °C for 30 s in a StepOne Real-Time PCR Sys-
tem (Applied Biosystems). Specific primers for IFN-λ1,
IFN-β, OAS1 and MX1 genes were designed using Probe-
Finder Assay Design Software (Roche, Basel, Switzerland,
www.universalprobelibrary.com) in order to use the
Taqman probes of Universal ProbeLibrary Set, Human
(Roche). In all cases, HPRT1 (Hypoxanthine Guanine
Phosphoribosyl Transferase) gene was used as an internal
control to determine the relative expression of each gene.
All primers were purchased from Integrated DNA Tech-
nologies (Coralville, IA, USA). Obtained Ct values were an-
alyzed by the 2 −ΔΔCt method, and the expression levels
were reported as proportions with respect to controls. Se-
quences of primers and probes are shown in Table 1.
ELISA
Levels of IFN- λ in the serum of patients were measured
using enzyme-linked immunosorbent assay (ELISA) kit
specific for IFN-λ1 and λ3 (DY1598B, R&D systems, Inc.
Minneapolis, USA). The ELISA was performed accord-
ing to the manufacturer’s instructions.
Statistical analysis
Quantitative analyses were performed in triplicate in
at least two different assays. Two-way ANOVA and
Bonferroni test were performed using GraphPad Prism 5
(GraphPad Software, La Jolla, CA, USA). Differences with
p < 0.05 were considered statistically significant.
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